Showing results (31-40 of 113) with videos related to

Sort By:
Pageof 12
Investigational New Drugs|May 6, 2009
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancerJan C Buckner, Bahram Forouzesh, Charles Erlichman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obeseAlex Sparreboom, Antonio C Wolff, Ron H J Mathijssen, et al.
Investigational New Drugs|October 16, 2009
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostainingRafal Wierzbicki, Derek J Jonker, Malcolm J Moore, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2011
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)Jordi Rodon, Charlotte D Jacobs, Quincy Chu, et al.
Journal of the National Cancer Institute|December 19, 2002
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001Sharyn D Baker, Jaap Verweij, Eric K Rowinsky, et al.
Investigational New Drugs|June 11, 2003
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancerE Claire Dees, Eric K Rowinsky, Dennis A Noe, et al.
Investigational New Drugs|January 24, 2007
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomasQuincy S C Chu, Bahram Forouzesh, Samira Syed, et al.
Current Drug Targets|July 23, 2011
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancersEric K Rowinsky, Jonathan D Schwartz, Naseem Zojwalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumorsCharles Erlichman, Manuel Hidalgo, Joseph P Boni, et al.
Investigational New Drugs|February 25, 2010
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junctionJuan W Valle, Anne Armstrong, Chris Newman, et al.
Pageof 12